As previously reported, BofA upgraded Hims & Hers (HIMS) to Neutral from Underperform with a price target of $23, up from $12.50. As part of the agreement with Novo Nordisk (NVO), the Wegovy maker has dropped its lawsuit, which the firm calls “a clear positive” as it removes litigation and related credit risk. While the firm remains “significantly below the Street” on revenue and EBITDA estimates for 2026 and 2027, it sees the risk/reward as balanced at current levels, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers upgraded to Neutral from Underperform at BofA
- Hims & Hers price target raised to $28 from $25 at Deutsche Bank
- Citi upgrades Hims & Hers to Neutral on Novo pact renewal
- Hims & Hers upgraded to Neutral from Sell at Citi
- Needham Upgrades Hims & Hers Stock (HIMS) after Novo Nordisk Deal Resets Weight Loss Outlook